Search clinical trials for: BIIL 284 BS, medium dose, pediatric patients

Total 36 results

Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

Cystic Fibrosis
Boehringer Ingelheim

Completed

Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis

Arthritis, Rheumatoid
Boehringer Ingelheim

Completed

Effect of Treatment With BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

Cystic Fibrosis
Boehringer Ingelheim

Completed

Pharmacokinetics, Safety and Efficacy of BIIL 284 BS in Patients With Rheumatoid Arthritis (RA)

Arthritis, Rheumatoid
Boehringer Ingelheim

Completed

Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Study to Investigate the Safety, Tolerability, Biological Effects and Preliminary Pharmacokinetics of Increasing Doses of BIIL 284 BS in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Relative Bioavailability, Safety and Tolerability of Two Tablet Formulations of BIIL 284 BS

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy Volunteers

Hepatic Insufficiency
Boehringer Ingelheim

Completed

The Effect of BIIL 284 BS on Induced-sputum Variables in Patients With Bronchial Asthma

Asthma
Boehringer Ingelheim

Completed

Effect of BIIL 284 BS on Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Terminated

Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and Pediatric Patients

Cystic Fibrosis

United States
Boehringer Ingelheim

Completed

Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C]-BIIL 284 BS in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Effect of Different Food Compositions on Bioavailability of BIIL 284 BS in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Increasing Repeated Doses of BIIF 1149 BS in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis

Psoriasis
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BIBW 2948 BS for HandiHaler® in Healthy Male Volunteers

Healthy
Chroma Therapeutics

Terminated

Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Boehringer Ingelheim

Completed

Study to Evaluate the Effect of Multiple Doses of BIIL 284 BS on the Pharmacokinetics of Prednisone in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacodynamics of BIIF 1149 BS in Healthy Young Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Study of New Tablet Formulations and Suspension Formulation Compared to Current (1B) Formulation of BILR 355 BS in Healthy Male Volunteer Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
Boehringer Ingelheim

Completed

BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
Boehringer Ingelheim

Completed

Effect of BIIL 284 BS on the Pharmacokinetics of Theophylline in Healthy Male Volunteers

Healthy
AstraZeneca

Recruiting

An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia (PEDZ-K)

Hyperkalaemia

China, Germany, United States, Ukraine, Spain, Japan, United Kingdom, Canada, Poland, Romania, Russian Federation, Brazil
Jessa Hospital

Recruiting

High Versus Low Dose Serratus Anterior Plane Block After Minimally Invasive Valve Surgery.

Analgesia | Surgery | Post Operative Pain | Cardiac Disease

Belgium
Memorial Sloan Kettering Cancer Center
Pfizer; Dana-Farber Cancer Institute; University of Pittsburgh; University of Virginia

Completed

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

Neurofibromatosis | Meningioma | CNS Cancer | Hemangioblastoma | Intracranial Hemangiopericytoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer

Rectal Cancer

United States
Assistance Publique Hopitaux De Marseille

Unknown

Efficacy of Lidocaine Versus Placebo in Palliative Care Patients With Opioid-refractory Cancer Pain With Neuropathic Component: a Multicenter, Prospective, Double-blind Randomized Placebo-controlled Study. (LIDOSP)

Cancer | Pain With Neuropathic Component

France
Wuhan Union Hospital, China
Peking University First Hospital

Recruiting

High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention Program

Cardiovascular Diseases | Coronary Disease | Diabetes Mellitus, Type 2

China
Selcuk University

Completed

Hypertonic Saline Enhances The Field of View of Clinicians and Ease of Procedures

Nasopharyngeal Diseases
National Institute of Diabetes and Digestive and...
Ann & Robert H Lurie Children's Hospital of Chicago

Recruiting

TReatment for ImmUne Mediated PathopHysiology (TRIUMPH)

Hepatic Encephalopathy | Acute Liver Failure | Fulminant Hepatic Failure | Acute Liver Injury | Immune Dysregulation

United States
UMC Utrecht
National University Hospital, Singapore; Berry Consultants; University of Pittsburgh... and other collaborators

Recruiting

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (REMAP-CAP)

Community-acquired Pneumonia, Influenza, COVID-19

United Kingdom, United States, Canada, Australia, Netherlands, Croatia, Germany, Belgium, New Zealand, Ireland, Spain, Japan, Hungary, Colombia, India, Nepal, Pakistan, Portugal, Romania, Saudi Arabia
National Cancer Institute (NCI)

Active, not recruiting

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes (The INSPIRE Study)

Stage III Bladder Cancer AJCC v8 | Bladder Urothelial Carcinoma

United States
M.D. Anderson Cancer Center

Recruiting

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Recurrent Adult Lymphoblastic Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia | Refractory Lymphoblastic Lymphoma

United States

3

Subscribe